4D-150 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

NCTID	NCT05197270 (View at clinicaltrials.gov)
Description	Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment (Show More)
Indication	Neovascular (Wet) Age-Related Macular Degeneration
Compound Name	4D-150
Sponsor	4D Molecular Therapeutics
Funder Type	Industry
Status	Recruiting
Enrollment Count	215

Target Gene/Variant	Anti-VEGF
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Genetic delivery of therapeutic protein
Route of Administration	Intravitreal
Drug Product Type	Viral vector
Target Tissue/Cell
Delivery System	Viral transduction
Vector Type	AAV
Editor Type
Dose 1	1 x 10^10 vg/eye
Dose 2	3 x 10^10 vg/eye
Dose 3	Planned Phase III dose: 3x10^10 vg/eye
Dose 4
Dose 5

No.of Trial Sites	24
Locations	Puerto Rico,United States

Has US IND	True
Recent Updates	Phase III trial to begin Q1 2025